Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.

@article{Chancellor2008EfficacyOS,
  title={Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.},
  author={Michael B Chancellor and Norman R. Zinner and Kristene Whitmore and Kathleen C. Kobashi and Jeffrey Aaron Snyder and Paul F. Siami and Mickey M. Karram and Christine Laram{\'e}e and James P Capo' and Raafat Seifeldin and Sergio Forero-Schwanhaeuser and Indrani M Nandy},
  journal={Clinical therapeutics},
  year={2008},
  volume={30 10},
  pages={
          1766-81
        }
}
OBJECTIVE This study evaluated the use of solifenacin in patients experiencing residual urgency symptoms during treatment with tolterodine extended release (ER) 4 mg for overactive bladder (OAB). METHODS This was a 12-week, multicenter, openlabel, flexible-dose study of the efficacy, tolerability, and effects on health-related quality of life (HRQL) of solifenacin in patients aged >or=18 years who had symptoms of OAB for >or=3 months, had been treated with tolterodine ER 4 mg for >or=4 weeks… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 20 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 35 REFERENCES

Similar Papers

Loading similar papers…